Literature DB >> 28214504

Frequency of Troponin Testing in Inpatient Versus Outpatient Settings.

Adam J Farber1, Keith Suarez1, Kipp Slicker1, Chhaya D Patel2, Brandon Pope3, Robert Kowal3, Jeffrey B Michel4.   

Abstract

Troponin elevation is required to diagnose acute myocardial infarction (AMI), yet elevated values are often encountered in noncardiac disease states. We evaluated inpatient (IP) and outpatient (OP) encounters at 14 hospitals in calendar year 2014 and found that troponin assays were performed during 12% of all OP visits and 29% of all IP visits: 82,853 encounters in all. We employed an expert panel to estimate the likelihood of AMI based on primary International Statistical Classification of Diseases and Related Health Problems, 9th edition diagnoses. We compared IP and OP testing, finding that AMI would not be expected in most IP encounters. Sepsis was the most common diagnosis associated with IP troponin testing. We found an association between troponin testing in patients with sepsis and utilization of electrocardiography, echocardiography, and cardiac catheterization. Our data indicate that troponin testing has expanded beyond patient populations in whom AMI might be expected.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28214504     DOI: 10.1016/j.amjcard.2016.12.030

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Decoding Acute Myocardial Infarction among Patients on Dialysis.

Authors:  Charles E Howard; Peter A McCullough
Journal:  J Am Soc Nephrol       Date:  2017-04-12       Impact factor: 10.121

2.  The trouble with troponin.

Authors:  Jeffrey B Michel; Jeffrey M Schussler
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-03-15

3.  Troponin I Cutoff for Non-ST-Segment Elevation Myocardial Infarction in Sepsis.

Authors:  Meng-Ko Tsai; Chao-Hung Lai; Chia-Lien Hung; Keng-Yi Wu
Journal:  Mediators Inflamm       Date:  2022-05-27       Impact factor: 4.529

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.